WO1995006407A1 - Nouveau composant amyloide lie a la maladie d'alzheimer et procedes d'utilisation - Google Patents

Nouveau composant amyloide lie a la maladie d'alzheimer et procedes d'utilisation Download PDF

Info

Publication number
WO1995006407A1
WO1995006407A1 PCT/US1994/009789 US9409789W WO9506407A1 WO 1995006407 A1 WO1995006407 A1 WO 1995006407A1 US 9409789 W US9409789 W US 9409789W WO 9506407 A1 WO9506407 A1 WO 9506407A1
Authority
WO
WIPO (PCT)
Prior art keywords
nac
nacp
peptide
amyloid
reagent
Prior art date
Application number
PCT/US1994/009789
Other languages
English (en)
Inventor
Eliezer Masliah
Original Assignee
The Regents Of The University Of California
Saitoh, Tsunao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Saitoh, Tsunao filed Critical The Regents Of The University Of California
Publication of WO1995006407A1 publication Critical patent/WO1995006407A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to diagnosis and treatment of neuronal abnormalities, in particular the deposition of amyloid plaques characteristic of Alzheimer's Disease.
  • AD Alzheimer's disease
  • PHF paired helical filaments
  • a senile plaque commonly comprises a mass of disorganized neurites surrounding a deposit of extracellular filaments of an amyloid polypeptide called A4 or ⁇ amyloid protein ("A/3").
  • Deposition of fibrillar deposits of A ⁇ a 39/43 residue amyloid is considered the pathological hallmark of AD.
  • molecular cloning based on the sequence of the A ⁇ protein indicated that it is encoded as part of a larger precursor (PreA4) that maps to chromosome 21 (Kang, et al., Nature, 325:733- 736, 1987; Goldgaher, ef al., Science, 235:877-880, 1987; Tanzi, et al., Science, 235:880-884, 1987; Robakis, et al., Proc. Natl. Acad. Sci. 84:4190- 4194, 1987).
  • PreA4 751 and PreA4 770 Two other forms of PreA4 (PreA4 751 and PreA4 770) contain a 56 residue insert which has a protease-inhibitory function.
  • the amyloidogenic A4 protein is derived in part from the transmembrane domain and from part of the adjacent extracellular domain. A precursor-product relationship has been demonstrated.
  • the A4 gene is expressed in brain and peripheral tissues, such as muscle and epithelial cells (Goeder, EMBO J., 6:3627-3632, 1987; Bahmanyar, et al., Science, 237 . :77-88, 1987; Zimmerman, et al., EMBO J., 7:1365-1370, 1988; Shivers, et al., EMBO J., 7:1365-1370, 1988), yet for reasons still unknown, the amyloid deposits in AD are confined to the brain. Recently, in situ hybridization analyses were published that indicate an alteration of the amount of PreA4 mRNA in brains of AD patients when compared to normal individuals (Higgins, et al., Proc.
  • amyloid In addition to A ⁇ , heparan sulfate proteoglycan, ferritin, immunoglobulins, and many acute phase proteins such as ⁇ -1 antichymotrypsin, apolipoprotein E, complements, serum amyloid P, and trace peptides have been reported to be associated with amyloid. However, supportive biochemical data demonstrating the presence of these proteins in amyloid preparations from the brains of Alzheimer's victims are not yet available, raising the possibility that these may not be intrinsic components of amyloid.
  • amyloid in amyloid deposits show a significant 0-pleated sheet component (Snow, A.D., et al., 1987). Yet the precursor of amyloid A ⁇ protein is soluble and does not exhibit a significant 3-pleated sheet component.
  • apolipoprotein E binds A ⁇ ⁇ Proc. Natl. Acad. Sci. USA, 90:1977-1981 , 1993).
  • apolipoprotein E may act as a molecular chaperone that mediates the ⁇ -pleated amyloid formation of A ⁇ as suggested by T. Wisniewski, et al. ⁇ Neurosci. Lett., 135:235-238, 1992).
  • amyloid deposition might be the result of aberrant processing of APP, and its abundance is an important parameter to consider in diagnosing the disease on a neuropathological basis.
  • cognitive dysfunction that characterizes AD is apparently attributable to synaptic loss (Terry, et al., Ann.Neurol., 30:572-580 (1993); Mattson, ef al.,
  • AD is related to neuritic plaques and synaptic loss
  • diagnosis of the disease is difficult.
  • the only way of confirming the presence of these lesions in a living patient is by brain biopsy.
  • this technique is rarely utilized because of the substantial risks to the patient involved in performing it.
  • AD is usually diagnosed on the basis of clinical symptoms and the results of neuropsychological tests. Nonetheless, because AD can be mimicked by other disorders (such as depression), confirmation of an AD diagnosis often cannot be conclusively made until autopsy.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • Novel peptides obtained by purification and analysis of the amino acid sequences in an amyloid preparation of brain tissue obtained from patients with symptoms of Alzheimer's disease have been shown to be fragments of a novel amyloid component ("NAC").
  • NAC novel amyloid component
  • Antibodies were raised against synthetically produced fragments of these novel peptides and used in immunohistochemical and electron microscopic analyses demonstrating that the peptides are localized in amyloid fibrils in AD brain tissue and are amyloidogenic.
  • cDNA Complementary DNA
  • NACP is a 140 amino acid protein identified as the precursor (“NACP”) of NAC.
  • NACP is a highly abundant synaptic protein, which degrades to form NAC.
  • NAC is self-aggregating; i.e., it has a significant ability to bind to itself and become part of amyloid fibrils and neuritic plaque.
  • the invention therefore provides NAC and NACP peptides useful as ligands to identify and quantify syanpses and plaques toward diagnosis and monitoring of diseases associated with synaptic loss and neuritic plaque formation, such as AD.
  • the invention also provides methods for treatment of such diseases.
  • a detectably labelled NAC/NACP peptide which will specifically bind NAC deposits in brain tissue is administered parenterally to a mammal (preferably a human). Binding of the administered peptide to NAC/NACP in brain tissue is detected using suitable in vivo diagnostic imaging techniques. Most preferably, this detection will be by positron emission tomography (PET) or single photon emission computed tomography (SPECT). ln another aspect of the invention, the binding data generated as described above is evaluated with any clinical signs of a neuropsychological disorder to assist in confirmation or refutation of an initial diagnosis of AD.
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • the binding data reveals the extent of amyloid deposition
  • the data may also be used to evaluate the prognosis for a patient with a confirmed diagnosis of AD.
  • the diagnostic method of the invention will provide physicians with valuable information concerning the medical status of a patient who is suspected of suffering from AD.
  • the binding data described above is evaluated with the results of tests for synapse loss in brain tissue to assist in confirmation of an AD diagnosis and to evaluate the prognosis for the patient.
  • Data evidencing a relationship between amyloid deposition and synapse loss in AD brain tissue will also be of use in research toward understanding the etiology of AD.
  • labelled NAC/NACP peptides are utilized in in vitro studies of amyloid deposition in sections of brain tissue for use in confirming an AD diagnosis and/or for research purposes.
  • in vitro (and in vivo) use of detectably labelled NAC/NACP peptides may be used
  • Figure 1 A shows immunohistochemical staining with anti-NAC antibodies of amyloid in diffuse, primitive, and mature plaques on slides of brain sections from patients with symptoms of Alzheimer's disease.
  • Panel A hippocampal sections were stained with anti-NAC antibody, anti-X1.
  • Panel B in addition to amyloid staining, occasional staining of dystrophic neurites (arrows) was detected with a anti-NAC antibody, anti-Y. Absorption with the corresponding peptide eliminated the staining.
  • Panel C shows absence of immunohistochemical staining by anti-sera to NAC on slides of AD brain sections when pre-absorbed with NAC peptides.
  • Panel D shows an electron micrograph of specific staining by anti-X1 antibody on amyloid fibrils (arrows) in AD brain sections. Amyloid fibrils were also stained with anti-Y antibody.
  • Figure 2 A shows the nucleotide sequence of cDNA encoding the precursor of the NAC protein and the 140 amino acid sequence of the NAC precursor protein encoded by a 420 bp open reading frame with the X and Y fragments located contiguously in the middle of the precursor.
  • the nearest in-frame stop codon (TAA) upstream to the putative initiation methionine codon is marked by an asterisk.
  • the termination codon is marked by two asterisks.
  • Sequence for X and Y peptides are boxed.
  • Synthetic oligonucleotide mixtures used for PCR are indicated as lines above the corresponding cDNA. Polyadenylation signals are underlined.
  • Figure 2 B is a graph showing the hydropathy profile of the NAC precursor protein with the NAC region being the most hydrophobic.
  • Figure 3 is a Western blot of brain homogenate with anti-NAC polyclonal antibody anti-X1.
  • NAC precursor protein in lane 4 is detected as a M r 19K protein.
  • the bacterially expressed NAC precursor protein expressed in E. coli transfected with pSENACP migrated in lanes 2 and 5.
  • Lanes 1 and 6 contain E. coli transfected with pSE380 vector control; and lanes 3 and 4 show normal human brain.
  • Lanes marked with (+) indicate X1 antibody was preabsorbed with X1 peptide; while those marked (-) indicated X1 antibody was preabsorbed with a control peptide.
  • the arrow indicates NACP detected as a M r 19K protein whose staining was blocked by preabsorption of the antibody with X1 peptide, thus showing specificity of the antibody.
  • Figure 4 A is a sequence listing of seven repeated sequence motifs in the NAC precursor amino acid sequence.
  • Figure 4 B is a sequence listing showing homology in the NAC precursor amino acid sequence at amino acids 48-56 and 70-78. Bold letters indicate the common amino acids among the repeat.
  • Figure 4 C is a comparison of the cDNA listings of EST01420 (EMBL/GenBank Libraries) and the NAC precursor showing homology therebetween at the N- terminal region of NAC.
  • Figure 5 is a Northern Blot of mRNA for NACP.
  • Lane 1 shows normal adult midfrontal cortex (female, aged 88); lane 2 shows cerebellum from the same individual as lane 1 ; lane 3 shows fetal whole brain (female, 24 week fetus); lane 4 shows midfrontal cortex from individual with AD (female, aged 83); lane 5 shows cerebellum from the same individual as Lane 4; lane 6 shows normal adult liver (male, aged 18); lane 7 shows normal child lung (male, aged 7).
  • Figure 6 A depicts self-aggregation of NAC peptide at various times and peptide concentrations (10-300 ⁇ M) as measured by turbidity at OD 400 nm. The NAC aggregation was studied in PBS (pH 7.4) solution at 37° C.
  • Figure 6 B depicts self-aggregation of NAC peptide (concentration, 300 ⁇ M) at various times and temperatures (4°, 22°, and 37 °C) as measured by turbidity at OD 400 nm.
  • the NAC aggregation was studied in PBS (pH 7.4) solution.
  • Figure 7 is a Western blot analysis of NAC peptide aggregation.
  • a NAC peptide monomer migrated at an apparent molecular mass of the 3500 Da.
  • the signal intensity of 3500 Da band was significantly decreased on Days 5 and 7.
  • aggregated NAC peptide was found at the top of the gel. This signal increased to a maximum by Day 3. No intermediate-size bands were observed.
  • Figures 8A and B show birefringence of Congo red-stained NAC peptide viewed by cross-polarization microscopy. Bright-field (A) and cross-polarized light (B) pictures of NAC peptide preparation stained with Congo red are shown.
  • Figure 9 is an electron micrograph of aggregated NAC peptide.
  • FIGS 10 A through D show (both macro- and microscopically) immunostaining of NACP in rat brain using anti-NACP(131-140) with streptavidin-biotin-peroxidase (SAB) method.
  • FIGURE 10 A is a macroscopic image of stained sagittal brain section showing that NACP immunoreactivity was relatively strong in the neocortex, olfactory region, caudoputamen, hippocampus, and cerebellar cortex compared to the thalamus and brain stem. Higher magnification microscopic analysis showed a characteristic granular immunoreactivity throughout the brain.
  • FIGURE 10 B is a microscopic image of stained cerebellar cortex.
  • FIGURE 10 C is a microscopic image of stained hippocampal dentate gyrus.
  • FIGURE 10 D is a microscopic image of stained cerebral cortex.
  • Figures 11 A through I are photographs obtained by laser scanning confocal microscopy of sections double-labeled for SY38 (mouse monoclonal anti- synaptophysin antibody; labeled with FITC and shown by bright patches in panels A, D and G) and NACP(131 -140/SEQ.ID.NO.6; shown by bright patches in panels B, E and H).
  • the right hand panels (C, F and I) correspond to the electronically merged image; colocalization of NACP with synaptophysin is indicated by bright patches.
  • Panels A-C are derived from staining of neocortex tissue; panels D-F are derived from staining of glomeruli of the olfactory bulb; and, panels G-l are derived from staining of the cerebellar cortex.
  • the scale bar (a horizontal white line across the lower right hand corner of panel A) is equal to 15 ⁇ m.
  • Figure 12 is a bar graph developed by computer-aided quantification of colocalization of NACP with synaptophysin in the presynaptic terminals of rat brain tissue. In the cortical regions a large percentage of the synpatophysin- immunoreactive terminals contained NACP. In contrast, in subcortical regions, a lower proportion of the synapatophysin-immunoalabeled axosomatic nerve terminals contained NACP.
  • Figure 13 is a photograph obtained by immunoelectron microscopy which reveals the synaptic vesicle membrane localization of NACP. Vibratome sections were immunostained with anti-NACP(131-140) and analyzed by electron microscopy.
  • Figure 14 is a Western blot quantifying NACP, APP, and synaptophysin in rat brain sections. Immunostaining of NACP, APP, and synaptophysin bands was carried out using anti-NACP(131 -140), mouse monoclonal antibody, 22C11 , and mouse monoclonal antibody, SY38, respectively. Signal intensity was quantified by scanning by a densitometer. Each value is shown as relative amount of protein normalized to the value in frontal cortex. NACP is highly concentrated in olfactory bulb, frontal cortex, striatum, and hippocampus , whereas APP and synaptophysin are distributed uniformly throughout the brain.
  • Figure 15 A-B shows, in bar graph form, the number of NACP containing and synaptophysin containing synaptic terminals present per 100 sq/ / _m of human frontal cortex brain tissue.
  • Figure 15 C-D shows, in bar graph form, the pixel intensity detected per synapse of human frontal cortex brain tissue indicative of the average quantities of NACP and synaptophysin contained in each synapse.
  • the solid bars are indicative of the values obtained in brain tissue from persons without AD; the slashed bars are indicative of the values obtained in brain tissue from persons suffering from AD.
  • Figure 16 shows immunolabeling of NACP and synaptophysin in human brain tissue obtained from a healthy person (upper panels) and from a person suffering from AD (middle panels).
  • the left and right images from the middle panel are electronically merged in the lower panel. Areas showing the brightest in the lower panel indicate colocalization of NACP and synaptophysin.
  • Figure 17 shows immunolabeling of NACP and synaptophysin in mature plaques (the 2 upper left hand panels) and in diffuse plaques (the 2 upper right hand panels).
  • the left and right images from the upper panels are electronically merged in the lower panel. Areas showing the brightest in the lower panel indicate colocalization of NACP and synaptophysin.
  • Figure 18 shows immunolabeling of ⁇ -amyloid (left hand panels) and NAC (right hand panels, with results electronically superimposed on the left hand panels) in brain tissue from healthy, elderly persons (panels A and B), from persons suffering from the early stages of AD (panels C and D), and from persons suffering from advanced stages of AD.
  • NAC amyloid component
  • NAC shall mean Non-Aj9 component of AD amyloid.
  • a ⁇ as used herein shall mean fibrillar deposits of the A4 protein, a 39/43 residue amyloid.
  • AD Alzheimer's Disease
  • NAC associated amyloid disorder shall refer to diseases associated with the excessive formation of amyloid in brain tissue, concommitant synaptic loss, and related cognitive dysfunction. This novel component of amyloid was discovered by analysis of the entire amino-acid sequences in an amyloid preparation of the frontal cortex of patients with typical neuropathological features of Alzheimer's disease (AD) using methods of purification in SDS and sequencing well known in the art.
  • NAC is the second intrinsic component after A ⁇ to be found in AD amyloid.
  • NAC which is expressed as a larger precursor polypeptide NACP
  • Copurification of NAC with amyloid in the presence of SDS and immunological localization on amyloid fibrils at the electron microscopic level shows that NAC is localized in neuritic plaques and amyloid fibrils.
  • NACP is encoded by a 1560 base pair polynucleotide (SEQ. I.D. NO. 1) with a 420 bp open reading frame which encodes a 140 amino acid polypeptide NACP (SEQ. I.D. NO.
  • NACP is recovered in the cytosolic fraction of human brain homogenate as a protein with an apparent molecular mass of 19,000 Da.
  • NACP has seven repeated KTKEGV amino acid motifs, but no signal petide sequence nor N- linked glyclosylation sites.
  • NAC is located in the most hydrophobic portion of NACP.
  • NAC is at least 35 amino acids and has a molecular weight of approximately Mr 3,500.
  • two new amyloid sequences have been identified and known herein as the "X and Y peptides", which are encoded contiguously in the most hydrophobic domain (SEQ. I.D. NOS. 4 and 5, respectively).
  • the definite length of NAC was not determined due to the use of enzymatic digestion in its preparation.
  • NAC neurofibrillary tangles
  • ATC ⁇ 1-antichimotrypsin
  • NAC Alzheimer's Disease
  • ATC has been reported to be localized on amyloid fibrils in brain tissue at the electron microscopic level (C. R. Abraham, et al., Cell, 52:487-501 , 1988)
  • NAC is both more specific to neuritic plaque and amyloid fibrils than ATC and less likely to be lost in preparation of tissues to be tested than ATC.
  • NAC is strongly hydrophobic and has characteristics associated with a tendency to form a ⁇ -pleated secondary protein structure.
  • NAC When synthesized chemically, NAC aggregates and precipitates easily in aqueous solution in a time, concentration and temperature-dependent manner. More particularly, synthetic NAC was detected initially as a monomer of 3500 Da, but became aggregated in aqeuous solution into a higher molecular weight molecule that could not migrate into an electrophoretic gel. On Congo red staining, the NAC aggregate showed green-gold birefringence when viewed with a poloarized light microscope and had a fiber-like structure when viewed through an electron microscope.
  • NACP is substantially present, if at all, in amyloid.
  • no other sequences of NACP besides the X and Y peptides were detected in the peaks eluted from HPLC analysis of the NACP protein.
  • NAC was identifed in immunostained amyloid on Western or dot blot, NACP was not.
  • NAC can form amyloid in vivo after cleavage from its precursor (NACP) and is likely to play a substantial role in amyloidosis.
  • the amyloid found in the brain tissue of humans with confirmed diagnoses of AD differs in structure from NAC aggregates alone, it is likely that NAC is not the sole component of amyloid. Rather, it is most probable that NAC is involved in the initial stages of amyloid formation, leaving the principal development of amyloidosis to the accumulation of ⁇ -amyloid.
  • NAC amyloidosis
  • anti-NACP 131-140
  • (1-9) immunostained the neuropil in a characteristic punctate pattern.
  • Neuronal cell bodies, glial cells and blood vessels were not immunostained.
  • NACP does not have a signal sequence, which suggests that NACP proteins remain localized in neuronal cytoplasm where NACP is expressed.
  • NAC can seep out of cells under certain conditions, such as serum deprivation.
  • the NACP protein is characterized by repetitive motifs.
  • the KTKEGV motif is repeated seven times, but the amino acid positions 2 to 6 are sometimes substituted.
  • amino acids 48-56 and 70-78 of the NACP protein are homologous. These repeated motifs can prove useful in determining the secondary and tertiary protein structure as well as the biological function and metabolism of this protein.
  • the threonine residues in the KTKEGV motif would offer favorable targets for protein kinase C (PKC).
  • PKC protein kinase C
  • the action of this enzyme is known to be critical in determining the functional state of neurons (Y. Nishizuka, Nature, 334:661-665, 1988).
  • NACP is detected in the cytosolic fraction of brain homogenates and comigrates on Western blots with NACP synthesized in E. coli from NACP cDNA.
  • NACP was not detected in a particulate fraction from human cortex or from NACP-expressing E. coli.
  • NACP mRNA is expressed principally in the brain, but is also expressed in low concentration in all tissues examined except in liver, suggesting that it has ubiquitous functions as well as brain specific functions.
  • NACP as a synaptic protein
  • search of the EMBL/GenBank DNA sequence databases reveals homologies between NACP and rat brain synucleins, the electric organ synpase of To ⁇ edo californica (Pacific electric ray) and to bovine phosphoneuroprotein 14, a brain specific protein present in synapses around neurons but not in glial cells and Purkinje cell bodies.
  • This group of small, acidic, brain-specific proteins have common repetitive sequence motifs and similar hydrophobic profiles (see.
  • NACP and EST01420 a human 223 bp sequence recently identified by random sequencing of human brain cDNA (M. D. Adams, ef al., Nature, 355:632-634, 1992). Comparison of the sequence of these proteins expressed in the human brain, as shown in FIGURE 4C, indicates the two proteins are substantially homologous in the N-terminal region, but the EST01420 sequence has the termination codon at base pair position 206, and, therefore, could encode only 51 amino acids.
  • NACP therefore appears to be a member of a family of synaptic proteins having hydrophobic regions centered in an otherwise hydrophilic molecule.
  • substantially pure means any NAC or NACP polypeptide of the present invention, or any gene encoding a NAC or NACP polypeptide, which is essentially free of other polypeptides or genes, respectively, or of other contaminants with which it might normally be found in nature, and as such exists in a form not found in nature.
  • the term "functional polypeptide” refers to a polypeptide which possesses a biological function or activity that is identified through a defined functional assay and which is associated with a particular biologic, morphologic or phenotypic alteration in the cell.
  • the biological function can vary from a polypeptide fragment as small as an epitope to which an antibody molecule can bind to as large as a polypeptide which is capable of participating in the characteristic induction or programming of phenotypic changes within a cell.
  • a “functional polynucleotide” denotes a polynucleotide which encodes a functional polypeptide as described herein.
  • preferred NAC/NACP polypeptides of the invention will be those which will effectively cross the blood/brain barrier without toxic effect.
  • NAC polypeptides of the invention will specifically bind NAC in vivo; the peptides will, therefore, have at least one binding site for NAC.
  • the NAC/NACP polypeptides should not be pathogenic or immunogenic.
  • the peptides are soluble and, in the case of NAC peptides, will reversibly bind NAC.
  • the polypeptides are preferably purified from a human or will be synthesized. "Synthesized” in this context refers to peptides produced through human intervention, whether by «_ chemical synthesis, recombinant genetic techniques or modification of an isolated native peptide.
  • NAC/NACP polypeptides used in the method of the invention may differ in amino acid sequence or structure but still retain the same biological activity as described above. Such modifications may be deliberately made (by, for example, site-directed mutagenesis) or may occur spontaneously. In either case, the invention will encompass the use of NAC/NACP peptides which have the same phenotype regardless of differences in structure and length between the peptides. These phenotypically similar peptides will be considered to "substantially similar" to one another.
  • a molecule On the molecular level, a molecule is said to be "substantially similar” to another molecule if the sequence of amino acids in both molecules is substantially the same. Substantially similar amino acid molecules will possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical. As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc.
  • the moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Penn. (1980). Minor modifications of the NAC primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the NAC polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity of NAC still exists. Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader utility. For example, one can remove amino or carboxy terminal amino acids which may not be required for NAC biological activity.
  • conservative variation denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like.
  • conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
  • a “fragment” of a molecule such as any of the DNA sequences of the present invention, includes any nucleotide subset of the molecule.
  • a “variant” of such molecule refers to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof.
  • An “analog” of a molecule refers to a non-natural molecule substantially similar to either the entire molecule or a fragment thereof.
  • a “functional derivative" of a gene encoding NACP polypeptide of the present invention includes “fragments”, “variants”, or “analogues” of the gene, including degenerate polynucleotides whose sequence may be determined readily by one of ordinary skill in the art, which encode a molecule possessing similar activity to a NAC peptide or fragment thereof.
  • NAC or NACP polypeptide and NAC or NACP polynucleotide include any functional derivative, fragments, variants, analogues, chemical derivatives which may be substantially similar to the NAC polypeptides and polynucleotides described herein and which possess similar activity.
  • Peptides of the invention can be synthesized by the well known solid phase peptide synthesis methods described Merrifield, J. Am. Chem. Soc, 85:2149, (1962), and Stewart and Young, Solid Phase Peptides Synthesis, (Freeman,
  • the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1 hours at 0°C. After evaporation of the reagents, the peptides are extracted from the polymer with 1% acetic acid solution which is then lyophilized to yield the crude material. This can normally be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent.
  • Lyophilization of appropriate fractions of the column will yield the homogeneous peptide or peptide derivatives, which can then be characterized by such standard techniques as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, solubility, and quantitated by the solid phase Edman degradation.
  • polynucleotide or "NACP polynucleotide” denotes DNA, cDNA and RNA which encode NACP polypeptide as well as untranslated sequences which flank the structural gene encoding NACP. It is understood that all polynucleotides encoding all or a portion of NACP polypeptide of the invention, such as the NAC polypeptide (s) are also included herein, as long as the encoded polypeptide exhibits the activity or function of NACP or the tissue expression pattern characteristic of NACP.
  • Such polynucleotides include naturally occurring forms, such as allelic variants, and intentionally manipulated forms, for example, mutagenized polynucleotides, as well as artificially synthesized polynucleotides.
  • mutagenized polynucleotides can be produced, for example, by subjecting NAC or NACP polynucleotide to site- directed mutagenesis.
  • a polynucleotide of the invention also includes in addition to NACP and/or NAC coding regions, those nucleotides which flank the coding region of the NACP structural gene.
  • a polynucleotide of the invention includes 5' regulatory nucleotide sequences and 3' untranslated sequences associated with the NACP structural gene.
  • the polynucleotide sequence for NACP also includes antisense sequences.
  • the polynucleotides of the invention also include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, as long as the amino acid sequence of NACP results in a functional polypeptide (at least, in the case of the sense polynucleotide strand), all degenerate nucleotide sequences are included in the invention. Where the antisense polynucleotide is concerned, the invention embraces all antisense polynucleotides capable of inhibiting production of NACP polypeptide.
  • the preferred NACP cDNA clone of the invention is defined by a sequence of 1560 basepairs, in accordance with the transcript of 1.6 kb. A minor transcript of 3.6 kb is also found.
  • the sequence surrounding the predicted initiator methionine codon (GCCATGG) agrees with the Kozak consensus sequence according to K. Kozak (Nucleic Acids Res., 15:8125-8148, 1987).
  • the nearest in-frame stop codon is found 18 bp upstream of the ATG initiation codon.
  • the nucleotide sequences encoding the X- and Y- peptide sequences are localized contiguously in the middle of the precursor peptide at bp 233 to 337.
  • the preferred NACP cDNA clone is characterized by the lack of a sequence encoding a signal peptide and by the lack of N- linked glycosylation sites.
  • DNA sequences of the invention can be obtained by several methods.
  • the DNA can be isolated using hybridization procedures which are well known in the art. These include, but are not limited to : 1) hybridization of probes to genomic or cDNA libraries to detect shared nucleotide sequences;
  • Hybridization procedures are useful for the screening of recombinant clones by using labeled mixed synthetic oligonucleotide probes where each probe is potentially the complete complement of a specific DNA sequence in the hybridization sample which includes a heterogeneous mixture of denatured double-stranded DNA.
  • hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA.
  • Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present.
  • a NACP containing cDNA library can be screened by injecting the various mRNA derived from cDNAs into oocytes, allowing sufficient time for expression of the cDNA gene products to occur, and testing for the presence of the desired cDNA expression product, for example, by using antibody specific for NACP or the X or Y peptide fragments thereof polypeptide or by using probes for the repeat motifs and a tissue expression pattern characteristic of NACP.
  • a cDNA library can be screened indirectly for NACP polypeptides having at least one epitope using antibodies specific for the polypeptides, such as X and Y peptides. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of NACP cDNA.
  • Oligonucleotide probes which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known.
  • the DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA.
  • hybridization is preferably performed on either single- stranded DNA or denatured double-stranded DNA.
  • Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present.
  • stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, et al., Nucl. Acid Res., 9:879, 1981).
  • DNA sequences encoding NACP can also be obtained by: 1) isolation of double-stranded DNA sequences from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
  • the isolation of genomic DNA isolates is the least common. This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.
  • DNA sequences are frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known.
  • the direct synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences.
  • the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned.
  • the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., Nucl. Acid Res., 11:2325, 1983).
  • a cDNA expression library such as lambda gt11
  • Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of NACP cDNA.
  • DNA sequences encoding NACP or NAC can be expressed in vitro by DNA transfer into a suitable host cell.
  • "Host cells” are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell” is used. Methods of stable transfer, in other words when the foreign DNA is continuously maintained in the host, are known in the art.
  • the NACP or NAC polynucleotide sequences may be inserted into a recombinant expression vector.
  • recombinant expression vector refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the NACP genetic sequences.
  • Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host.
  • the expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells.
  • Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, ef al., Gene, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem., 263:3521.
  • the DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein I, or polyhedrin promoters and enhancer).
  • a promoter e.g., T7, metallothionein I, or polyhedrin promoters and enhancer.
  • Polynucleotide sequences encoding NACP or NAC peptides can be expressed in either prokaryotes or eukaryotes.
  • Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art.
  • Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorpo ⁇ rate DNA sequences of the invention.
  • Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art.
  • the host is prokaryotic, such as E. coli
  • competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCI 2 method by procedures well known in the art.
  • CaCI 2 or RbCI can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.
  • Eukaryotic cells can also be cotransformed with DNA sequences encoding the NACP or NAC proteins of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene.
  • Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein.
  • a eukaryotic viral vector such as simian virus 40 (SV40) or bovine papilloma virus
  • SV40 simian virus 40
  • bovine papilloma virus bovine papilloma virus
  • transgenic mouse expressing a foreign gene utilize several techniques for inserting the foreign gene into the germline of the animal at an early developmental stage, such as at the single-cell level.
  • the transgene can be inserted into a mouse oocyte, which is then implanted into mouse for birth of a transgenic animal. See U. S. Patent No. 4,873,191 , "Genetic Transformaion of Zygotes," which is incorporated herein in its entirety.
  • pluripotent embroyo-derived stem (ES) cells can be modified extra- corporeally by insertion of a cloned gene to transfer a modification to the germ line of a living organism.
  • Homologous recombination has also been used for targeting genetic mutations to a predetermined genetic locus of an ES cell in order to produce a transgenic animal (Mansour, etal., Nature, 336:348, 1988; Capecchi, M., Trends Genet, 5:70, 1989).
  • Homologous recombination between DNA sequences residing in the chromosome and newly introduced cloned DNA sequences allows the transfer of any modification to the cloned gene into the genome of a living cell.
  • site-specific recombination systems are known (Craig, Ann. Rev. Genet, 22:77, 1988) including the FLP system of yeast and the Cre system of bacteriophage P1.
  • the FLP recombinase of the yeast saccharomyces cerevisiae acts on copies of a recombination target called
  • the FLP system has been shown to effect site-specific recombination in the Drosophilia genome in vivo (Golic, et al., Cell, 59:499, 1989, Golic, K., Science, 252:958, 1991) and in eukaryotic cells in vitro (O'Gorman, et al., Science, 251:1351 , 1991).
  • loxP prokaryotic Cre-loxP site-specific DNA recombination system of coliphage P1.
  • the 38 kD Cre protein efficiently causes both inter- and intra ⁇ molecular recombination between specific 34 base pair repeats termed loxP (Stemberg, ef al., J. Mol. Biol., 150:467, 1981).
  • Each loxP site contains two 13 base pair inverted repeats and an 8 base pair asymmetric core sequence. No accessory proteins are required for exchange to occur. Direct repeats of loxP dictate an excision of intervening sequences while inverted repeats specify inversion.
  • Cre has been shown to be functional in eukaryotic cells (Sauer, ef al., Nucleic Acids Res., 27:147, 1989) and in transgenic plants (Dale, ef al., Proc. Natl. Acad. Sci. USA, 88:10558, 1991).
  • U. S. Patent No. 5,175,383 discloses the method of making a transgenic mouse model for the human disease benign prostatic hypertrophy. To create the Harvard mouse the int-2 oncogene, which codes for a growth factor, was joined to a control gene to ensure that the growth factor would be produced in prostate tissue.
  • Patent Application WO 90/06367 entitled “Transgenic Mice for the Analysis of Hair Growth” wherein insertion of a promoter of a gene for a hair specific protein, one expressed only in tissues involved in hair growth, is used to regulate expression of a reporter gene. Due to conservation among homologous genes and their products, transgenes can be expressed in mice under the control of a regulatory sequence from a human tissue specific gene.
  • Patent Application WO 93/14200 which is incorporated herein by reference in its entirety, discloses creation of a trangenic mouse that expresses y9-amyloid precursor proteins.
  • the NAC polynucleotide in the form of an antisense polynucleotide is useful in treating disease states associated with formation of amyloid i.e., amyloidosis in the brain, (particularly in neuritic) plaques by preventing expression of the protein that is originating.
  • any disorder which is etiologically linked to expression of NACP could be considered susceptible to treatment with a reagent of the invention which modulates NACP expression.
  • modulate envisions the suppression of expression of NACP when it is over-expressed, or augmentation of NACP expression when it is under-expressed or when the NACP expressed is a mutant form of the polypeptide.
  • Such suppressive reagents as antisense NACP polynucleotide sequence or NACP binding antibody can be introduced to a cell.
  • a sense polynucleotide sequence (the DNA coding strand) or NACP polypeptide can be introduced into the cell.
  • the invention includes polyclonal and monoclonal antibodies immunoreactive with NACP or NAC polypeptides or immunogenic fragments thereof.
  • Antibodies which are specific for NAC or NACP may be produced by immunization of a non-human with antigenic NAC or NACP peptides of native or synthetic origin. Once antigenic peptides are prepared, antibodies to the immunizing peptide are produced by introducing peptide into a mammal (such as a rabbit, mouse or rat).
  • a multiple injection immunization protocol is preferred for use in immunizing animals with the antigenic MTA peptides (see, e.g., Langone, ef al., eds., "Production of Antisera with Small Doses of Immunogen: Multiple Intradermal Injections", Methods ofEnzymology (Acad. Press, 1981).
  • a good antibody response can be obtained in rabbits by intradermal injection of 1 mg of the antigenic MTA peptide emulsified in Complete Freund's Adjuvant followed several weeks later by one or more boosts of the same antigen in Incomplete Freund's Adjuvant.
  • the immunizing peptide may be coupled to a carrier protein by conjugation using techniques which are well-known in the art.
  • a carrier protein such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.
  • KLH keyhole limpet hemocyanin
  • BSA bovine serum albumin
  • tetanus toxoid tetanus toxoid.
  • the coupled peptide is then used to immunize the animal (e.g. a mouse or a rabbit).
  • Polyclonal antibodies produced by the animals can be further purified, for example, by binding to and elution from a matrix to which the peptide to which the antibodies were raised is bound.
  • a matrix to which the peptide to which the antibodies were raised is bound.
  • Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (see. for example, Coligan, et al., Unit 9, Current Protocols in Immunology, Wiley
  • polyclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which NAC polypeptide is bound.
  • a matrix to which NAC polypeptide is bound.
  • Those of skill in the art will know of various other techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies.
  • Antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided.
  • Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known to those skilled in the art (Kohler, ef al., Nature, 256:495, 1975).
  • the term antibody or, immunoglobulin as used in this invention includes intact molecules as well as genetically engineered antibody constructs such as bifunctional antibodies, CDR grafted antibodies, and the like, as well as fragments thereof, such as Fab and F(ab') 2 , which are capable of binding an epitopic determinant on NACP or NAC.
  • a preferred method for the identification and isolation of an antibody binding domain that exhibits binding with NACP or NAC peptides is the bacteriophage ⁇ vector system.
  • This vector system has been used to express a combinatorial library of Fab fragments from the mouse antibody repertoire in Escherichia coli (Huse, ef al., Science, 246:1275-1281 , 1989) and from the human antibody repertoire (Mullinax, ef al., Proc. Natl. Acad. Sci., 8Z:8095-8099, 1990).
  • receptors Fab molecules
  • Fab molecules exhibiting binding for a preselected ligand were identified and isolated from these antibody expression libraries.
  • Hybridomas which secrete a desired monoclonal antibody can be produced in various ways using techniques well understood by those having ordinary skill in the art and will not be repeated here. Details of these techniques are described in such references as Monoclonal Antibodies-Hybridomas: A New Dimension in Biological Analysis, Edited by Roger H. Kennett, et al., Plenum Press, 1980; and, U.S. Patent No. 4,172,124. F. METHODS FOR DETECTING AMYLOID OR A CELL EXPRESSING NACP.
  • the invention provides a method for detecting a cell expressing NACP, or an amyloid disorder associated with NAC, comprising contacting a cell suspected of expressing NACP or having a NAC associated disorder with a reagent which binds to the target component.
  • the cell component can be nucleic acid, such as DNA or RNA, or protein.
  • the reagent is a nucleic acid probe or PCR primer.
  • the reagent is an antibody probe.
  • the probes are detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator or an enzyme.
  • an antibody or nucleic acid probe specific for a cell for purposes of the invention, an antibody or nucleic acid probe specific for a cell
  • NACP or fragments thereof may be used to detect the presence of NACP polypeptide or NAC peptides (using antibody) or polynucleotide (using nucleic acid probe) in biological fluids or tissues. Any specimen containing a detectable amount of antigen can be used.
  • a preferred sample in this invention is tissue of brain origin, specifically midfrontal cortex tissue obtained through biopsy. More preferably, the tissue is hippocampus tissue. Preferably the subject is human.
  • Another technique which may also result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyl, pyridoxal, and fluorescein, which can react with specific anti- hapten antibodies.
  • the method for detecting a cell expressing NACP or a amyloid disorder associated with NAC can be utilized for prescreening for detection of amyloidosis prior to or after a subject's manifestation of typical clinical and neuropathological features of AD. Additionally, the method for detecting NACP polypeptide in cells is useful for prescreening to detect risk of amyloid disorder by identifying cells expressing NACP at levels different than normal cells. Using the method of the invention, high, low, and mutant NACP expression can be identified in a cell and the appropriate course of treatment can be employed (e.g., sense or antisense gene therapy).
  • the monoclonal antibodies of the invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier.
  • the monoclonal antibodies in these immunoassays can be detectably labeled in various ways.
  • types of immunoassays which can utilize monoclonal antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. .Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay.
  • Detection of the antigens using the monoclonal antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.
  • the monoclonal antibodies of the invention can be bound to many different carriers and used to detect the presence of NACP or NAC peptides such as X and Y. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such using routine experimentation.
  • epitopic determinants includes any determinant capable of specific interaction with the monoclonal antibodies of the invention.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • the concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having NAC or NACP is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.
  • NAC/NACP polypeptides that will cross the blood-brain barrier, and bind to the native protein are expected to be the best NAC/NACP ligands.
  • the preferred ligands of the invention will be those which are derived from positions 61-95 of the NACP amino acid sequence (i.e., in the NAC region), and from the C-terminal region of NACP (positions 131-140).
  • this preference is derived from the observation that antibodies to NAC (61-95) bind amyloid plaques, while antibodies to NACP (131-140) bind synapses, as well as the presumed ability of the peptides to cross the blood brain burner.
  • NAC is a self-aggregating peptide (which apparently derives from the 61 -95 amino acid region of NACP).
  • NACP peptide 1 which are derived from the 131-140 region of NACP; see. SEQ.ID.No.1
  • EGYQDYEPEAKKD NACP peptide 1
  • KKKEGYQDYEPEA NACP peptide 2
  • peptides shorter than NAC (61-95) or NACP (131-140) can be screened for use in the method of the invention by incubation with AD brain tissue homogenates or brain tissue from an animal model which has been implanted surgically with amyloid, or through immunological techniques such as those described above (e.g., testing the reactivity of anti-NACP antibodies that react with the native protein to the candidate ligand).
  • NACP peptide i.e., NAC or NACP candidate ligand
  • NAC or NACP candidate ligand has the same specificity as the NAC ligand described above by ascertaining whether the former prevents the latter from binding to NAC. If the candidate ligand competes with a ligand which is known to bind NAC/NACP (as shown by a decrease in binding by the latter), then the two peptides bind to the same, or a closely related site.
  • Still another way to determine whether a particular candidate ligand has the specificity of a ligand which is known to bind NAC/NACP is to preincubate the candidate ligand with NAC or NACP and then add a known ligand to determine if it is inhibited in its ability to bind NAC or NACP. If the known NAC/NACP ligand is inhibited, in all likelihood the candidate ligand has the same, or functionally equivalent, binding specificity as the known NAC/NACP ligand.
  • Screening of candidate ligands can also be determined by attaching a detectable label to them, incubating them with amyloid-containing brain tissue (in vivo or in vitro) and determining whether binding has occurred using in vivo diagnostic imaging techniques as described in more detail below.
  • NAC and NACP ligands may be labelled as described below; however, for in vivo diagnostic imaging, the use of radiolabels or paramagnetic isotopes will be preferred.
  • the type of detection instrument available is a major factor in selecting a given radioisotope.
  • the radioisotope chosen must have a type of decay which is detectable for a given type of instrument.
  • Still another important factor in selecting a radioisotope for in vivo diagnosis is that the half-life of the radioisotope be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host is minimized.
  • a radioisotope used for in vivo imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may be readily detected by conventional gamma cameras.
  • radioisotopes may be bound to proteinaceous ligands either directly or indirectly by using an intermediate functional group.
  • Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules.
  • DTPA diethylenetriaminepentacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • metallic ions which can be bound to the ligands of the invention are 111 ln, 97 Ru, 67 Ga, ⁇ Ga, 72 As, 89 Zr, and ⁇ Tl.
  • Radiolabelling with "Tc may be performed according to the technique described in Kasnia, ef al. J. Nucl. Med., 32: 1445-1451 , 1991.
  • 125 lodide ( 125 l) would be preferred for ease of detection.
  • 125 l may be attached to a NAC or NACP ligand for use in the invention by conventional techniques including oxidative radiodination using sodium 125 l and chloramine T (for tyrosine containing peptides) or the acylation followed by oxidative radiodination (for peptides not containing tyrosine).
  • lodination may also be performed using an iodination product from DuPont of
  • the ligands of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR).
  • MRI magnetic resonance imaging
  • ESR electron spin resonance
  • any conventional method for visualizing diagnostic imaging can be utilized.
  • gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI.
  • Elements which are particularly useful in such techniques include 157 Gd, ⁇ Mn, 162 Dy, ⁇ Cr, and ⁇ Fe.
  • the labelled ligands will preferably be purified by means well known in the art referred to above (for example, RP- HPLC) to an essentially quantitative specific activity (e.g., about 2000 Ci/mmol; 1Ci « 37GBq).
  • a diagnostically effective amount of a detectably labelled ligand as described above will be administered to mammal which is suspected of having AD, has been diagnosed as having AD or, in the research context, has had amyloid plaque formation induced in its brain tissue.
  • the mammal will be a human who is suspected of having or has been diagnosed as having AD.
  • the dosage of detectably labeled ligand for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual.
  • the dosage of monoclonal antibody can vary from about 0.001 mg/m 2 to about 500 mg/m 2 , preferably 0.1 mg/m 2 to about 200 mg/m 2 , most preferably about 0.1 mg/m 2 to about 10 mg/m 2 .
  • Such dosages may vary, for example, depending on whether multiple injections are given, amyloid burden, and other factors known to those of skill in the art.
  • the "diagnostically effective amount" of detectably labelled NAC ligand for in vivo applicants will be that amount which is sufficient to detectibly bind any NAC present in the subject brain tissue.
  • binding of the detectably labelled peptides of the invention is somewhat dose-dependent, it will be appreciated because the peptides are self-aggregating, increasing their dosage may intensify rather than expand the NAC binding pattern. More specifically, while binding of most or all of the NAC plaques present in the subject brain tissue may occur at lower dosage levels, the intensity of the emissions indicative of that binding may be enhanced as the detectably labelled peptide density per plaque is increased at higher dosage levels.
  • any nonsurgical route of administration which introduces the detectably labelled ligands of the invention into brain tissue may be used, intraarterial injection in preferred, with intracarotid injections being most pre ⁇ ferred.
  • the background measurement will preferably be established by determining the extent of binding of a detectably labelled ligand in healthy mammalian subjects.
  • measurements based on binding of the detectably labelled ligand indicative of the presence of > about 15 plaques/unit area will be considered to be diagnostically significant for (i.e., indicative of) AD.
  • These data can be used to assist in confirmation or refutation of a clinical diagnosis of AD.
  • the method of the invention can provide data of at least three significant types.
  • previous plaque density measurements taken from that subject would be used as background.
  • NACP ligand the probable progression of loss of cognitive function as well as the status of plaque formation through NACP cleavage, may be evaluated based on decreses in the synaptic population and/or increases in presynatpic bouton concentrations of NACP.
  • Binding will preferably be measured within one hour of introducing the detectably labelled peptide into the subject's bloodstream. Binding will be measured in vivo using well-known in vivo diagnostic imaging techniques (in particular computer assisted sectional radiography (tomography)), preferably during the first hour following administration of the detectably labelled peptide.
  • well-known in vivo diagnostic imaging techniques in particular computer assisted sectional radiography (tomography)
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • the NAC/NACP ligands may be used for in vitro studies, for example, binding affinity of different peptides, to develop anti- amyloid antibodies, to study the pathology of amyloid deposition and to evaluate proposed therapies.
  • the NAC/NACP peptides may be of particular use in developing in vivo means of differential diagnosis. For example, because NAC principally appears in mature plaques, the stage of AD development is a given patient may be identified more accurately by detecting NAC in vivo than is now possible using conventional diagnostic techniques.
  • the NAC/NACP ligands of the invention can be used to monitor the course of amelioration of NAC associated amyloid disorder.
  • the NAC/NACP ligands of the invention can be used to monitor the course of amelioration of NAC associated amyloid disorder.
  • by measuring the increase or decrease in the number of cells expressing NACP or changes in the concentration of normal versus mutant NACP or NAC present in various body fluids and/or tissues it would be possible to determine whether a particular therapeutic regiment aimed at ameliorating the disorder is effective.
  • the present invention also provides a method for treating a subject with a NAC associated amyloid disorder. Because the NACP nucleotide sequence can be expressed in an altered manner as compared to expression in a normal cell, it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. Thus, where an amyloid disorder is associated with the over-expression of NACP, nucleic acid sequences that interfere with NACP expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid and ribozymes to block translation of a specific
  • NACP mRNA either by masking that mRNA with an antisense nucleic acid or by cleaving it with a ribozyme.
  • nucleic acid sequences encoding NACP could be administered to the subject with the disorder.
  • NAC peptides that will cross the blood-brain barrier and bind to NAC (to "modulate" the accumulation thereof) are identified elsewhere above, as are means to identify any additional NAC peptides possessing this ability.
  • Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target NACP-producing cell. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, Anal. Biochem.,
  • Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
  • ribozymes There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and "hammerhead"-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while “hammerhead”-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that that sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
  • the present invention also provides gene therapy for the treatment of amyloid disorders which are mediated by NACP protein.
  • Such therapy would achieve its therapeutic effect by introduction of the NACP antisense polynucleotide, into target cells (i.e., in brain tissue) of subjects having the amyloid disorder.
  • Delivery of antisense NACP polynucleotide can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal disper ⁇ sion system.
  • Disorders associated with under-expression of NACP could similarly be treated using gene therapy with sense nucleotide sequences.
  • RNA virus such as a retrovirus
  • retroviral vector is a derivative of a murine or avian retrovirus.
  • retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV).
  • MoMuLV Moloney murine leukemia virus
  • HaMuSV Harvey murine sarcoma virus
  • MuMTV murine mammary tumor virus
  • RSV Rous Sarcoma Virus
  • Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding an enzyme that determines the structure of a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector.
  • helper cell lines that contain piasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These piasmids are missing a nucleotide sequence that enables the packaging mechanism to recognize an RNA transcript for encapsidation.
  • Helper cell lines which have deletions of the packaging signal include but are not limited to ⁇ 2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced.
  • NIH 3T3 or other tissue culture cells can be directly transfected with piasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.
  • colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid- based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • the preferred colloidal system of this invention is a liposome.
  • Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (LIN), which range in size from 0.2-4.0 um can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to brain cells in a biologically active form (Fraley, ef al., Trends Biochem. Sci.,
  • in vivo administration can be in a bolus or by gradual perfusion over time by means adapted for crossing the blood-brain barrier.
  • the NAC or NACP polynucleotides or polypeptides can be injected by epidural administration or intralumbar puncture using standard techniques well known to the medical profession, although an intrarterial route of administration would be preferred for patient comfort.
  • a liposome In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).
  • the composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used.
  • the physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phos- phatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides.
  • diacylphosphatidylglycerols where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
  • Illustrative phospholipids include egg phosphatidyl ⁇ choline, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
  • the targeting of liposomes has been classified based on anatomical and mechanistic factors.
  • Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific.
  • Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
  • a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein
  • the surface of the targeted delivery system may be modified in a variety of ways.
  • lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the Hposomal bilayer.
  • Various linking groups can be used for joining the lipid chains to the targeting ligand.
  • the compounds bound to the surface of the targeted delivery system will generally be ligands and receptors which will allow the targeted delivery system to find and "home in" on the desired cells.
  • a ligand may be any compound of interest which will bind to another compound; e.g., NAC.
  • receptors surface membrane proteins which bind to specific effector molecules are referred to as receptors.
  • antibodies are preferred receptors.
  • Antibodies can be used to target liposomes to specific cell-surface ligands. For example, certain antigenic sites associated with NAC polypeptides in amyloid formations may be exploited for the purpose of targeting NAC polypeptide or polynucleotide containing liposomes directly to the amyloid deposit. Since the NACP gene product may be indiscriminate with respect to cell type in its action, a targeted delivery system offers a significant improvement over randomly administered non-specific liposomes.
  • the target tissue is brain tissue and the target cell is a neuron/glia.
  • Antibody-targeted liposomes can include monoclonal or polyclonal antibodies or fragments thereof such as Fab, or F(ab') 2 , as long as they bind efficiently to an antigenic epitope on the target cells. Liposomes may also be targeted to cells expressing receptors for hormones or other serum factors.
  • kits may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of the container means comprising the separate elements of the assay to be used.
  • kits form are many, and include, for example, competitive and non-competitive assays.
  • Typical examples of assays which can utilize the antibodies of the invention are radioimmunoassays (RIA), enzyme immunoassays (EIA), enzyme-linked immunosorbent assays (ELISA), and immunometric, or sandwich immunoassays.
  • RIA radioimmunoassays
  • EIA enzyme immunoassays
  • ELISA enzyme-linked immunosorbent assays
  • sandwich immunoassays immunometric, or sandwich immunoassays.
  • immunometric assay or "sandwich immunoassay” includes simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.
  • the incubation medium usually added with the labeled soluble antibody.
  • the "blockers” are added to assure that non-specific proteins, proteases, or anti- heterophilic immunoglobulins to anti-NACP or anti-NAC immunoglobulins present in the experimental sample do not cross-link or destroy the antibodies on the solid phase support, or the radiolabeled indicator antibody, to yield false positive or false negative results.
  • the selection of "blockers” therefore may add substantially to the specificity of the assays described in the present invention.
  • nonrelevant antibodies of the same class or subclass (isotype) as those used in the assays e.g., lgG1 , lgG2a, IgM, etc.
  • concentration of the "blockers” normally 1 -100 is important, in order to maintain the proper sensitivity yet inhibit any unwanted interference by mutually occurring cross reactive proteins in the specimen.
  • the invention also relates to a method for preparing a medicament or pharmaceutical composition
  • a medicament or pharmaceutical composition comprising the polynucleotides, monoclonal antibodies or the NAC/NACP ligands of the invention ("pharmaceutically active molecules"), the medicament being used for therapy of NAC associated amyloid disorders.
  • Pharmaceutically active molecules will preferably be administered in a pharmaceutically acceptable carrier, which may include sterile aqueous of non- aqueous solutions, suspensions, and emulsions.
  • a pharmaceutically acceptable carrier may include sterile aqueous of non- aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • a pharmaceutically active molecule of the invention may be conjugated by means well known in the art to polyethylene glycol (PEG) to reduce its immunogenicity.
  • PEG polyethylene glycol
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxi- dants, chelating agents, and inert gases and the like.
  • Amyloid was purified from the frontal cortex of patients with typical clinical and neuropathological features of AD (obtained from the Alzheimer's Disease Research Center, San Diego, CA) using a modification of a protocol previously described by J. Kondo, ef al. (Neuron, 1:827-834, 1988). Briefly, AD cortex was homogenized in 2% SDS, 1 % 2-mercaptoethanol, 50 mM Tris-HCI, pH 7.6, heated to 95° C for 10 minutes, and then centrifuged at 100,000 x g for 60 minutes. The pellets were suspended in 50 mM Tris-HCI, pH 7.6, and 1% SDS (SDS buffer) and centrifuged at 100,000 x g for 60 minutes.
  • SDS buffer SDS buffer
  • the pellets were resuspended in 0.5 M sucrose in SDS buffer and subjected to 1.0/2.0 M sucrose step-gradient centrifugation at 245,000 x g for 2 hours.
  • the interfaces were collected and centrifuged at 150,000 x g for 60 minutes after 5 times dilution with SDS buffer.
  • the pellets recovered were sonicated in SDS buffer, dialyzed against 70% formic acid, cleaved with CNBr, and digested with Achromobacter lyticus protease I in 5 M urea at 30 °C for 5 hours.
  • the cleaved peptides were separated by HPLC on a C4 column with a linear gradient (0-80%) of acetonitrile/isopropanol (37) in 0.1% trifluoroacetic acid. All of the HPLC peaks eluted from HPLC were sequenced using methods known in the art. In addition to the major A ⁇ sequence (31.1 nmol) two heretofore unknown peptides X (2.0 nmol) and Y (2.3 nmol) were recovered.
  • NAC peptide X SEQ. I.D. NO. 4
  • NAC peptide Y SEQ. I.D. NO. 5
  • Proteins X and Y were synthesized using methods known in the art, tested for solubility, and found not to be soluble in any aqueous solution examined. Therefore, the N-terminal sequences of proteins X and Y were synthesized and used to raise rabbit antisera using methods known in the art. For example, a C-terminal cystein was added to the 9 N-terminal amino acids of protein X to form a protein fragment X1 EQVTNVGGAC (SEQ. I.D. NO. 6), and a C-terminal cystein was added to the 7 N-terminal amino acids of protein Y to form a protein fragment Y (TVEGAGSC) (SEQ. I.D. NO. 7). These protein fragments
  • X1 and Y were conjugated to KLH using MBS as described in N. Green, ef al., (Cell 28:477-487, 1982). Rabbits were boosted several times with the MBS- conjugated peptides, and then proteins X and Y were conjugated to KLH with glutaraldehyde, injected into rabbits, and antisera were obtained as described in E. Masliah, ef al. (J. Neurosci., 10:2113-2124, 1990).
  • Antisera obtained from the rabbits were used to perform immunohistochemical and immunoelectron microscope analysis of AD brain sections using methods known in the art (Masliah, supra, 1990; E. Masliah, etal. (J. Neurosci., 11:2759- 2767, 1991).
  • specificity of the staining was demonstrated by a pre-absorption experiment consisting of incubation of antibody X1 with peptide X1 and incubation of antibody Y with peptide Y.
  • the antisera were incubated with peptide of an entirely different sequence (EGYQDYEPEAC) (SEQ. I.D. NO. 8).
  • the sections were washed in PBS, incubated with biotinylated goat anti-rabbit IgG followed by avidin D-HRP (Vector ABC Elite, Vector Labs, inc., Burlingame, CA) and reacted with diaminobenzidine (DAB, 0.2 mg/ml) in 50 mM Tris buffer (pH 7.4) with 0.001% H 2 0 2 .
  • Control sections were incubated with preimmune serum.
  • the immunostained sections were postfixed for 20 minutes in 1% Os0 4 , dehydrated, and embedded to present a flat surface in epoxy/Araldite. Ultrathin sections were cut with a Reichert OM-U3 ultramicrotome and viewed with a 100 CX JEOL electron microscope.
  • FIGURE 1 Results of the immunohistochemical and immunoelectron microscope analysis of AD brain sections are shown in FIGURE 1.
  • Panel A shows hippocampal sections stained with antibodies anti-X1 and anti-Y.
  • Panel B occasional staining of dystrophic neutites (arrows) was detected with anti-Y antibody.
  • Immunostaining of amyloid in diffuse, primitive, and mature plaques was detected in Panels A and B. as well as in cerebral vessel walls (not shown) as revealed by double staining with thioflavin S. When these sera were preabsorbed with fragments X1 and Y, staining was eliminated.
  • Panel C neither preimmune sera nor antisera containing anti-X1 and/or anti-Y antibodies stained amyloid in AD brain tissue when antisera had been preabsorbed with the corresponding peptide fragments X1 and Y.
  • Panel D shows an electron micrograph of staining of amyloid fibrils (arrows) with anti-X1 antibody. Amyloid fibrils were also stained with the anti-Y antibody (not shown).
  • the anti-Y antibody stained not only amyloid in plaques, but also nuclei of small, possibly glial cells, cytoplasm of some small cells, and neuropil threads. The staining of these structures other than amyloid was not observed with the anti-X1 antibody.
  • This difference in staining may represent a genuine difference in the distribution of two products of a single precursor protein or, alternatively, it may be a result of a less specific staining by the anti-Y peptide antibody. It appears likely that the latter explanation is correct because anti-Y antibody stains dozens of bands on Western blots of brain extract (data not shown).
  • oligonucleotide primers for DNA flanking the EcoRI cloning site of ⁇ gt11 were made. PCR was performed using these oligonucleotides as primers with combinations of X1 (or X2) and Z (or ⁇ Z) as primers and a cDNA expression library of human brain tissue in ⁇ gtl 1 as template. Briefly, the PCR reaction was performed at 94°C for 1 minute, at 51 °C for 1.5 minute, and at
  • PCR DNA product of about 280 bp obtained from the combination of primers X2 and ⁇ Z was purified, digested with EcoRI, subcloned into the EcoRI-Hincll site of pBluescript SK+ (Stratagene, San Diego, CA), and sequenced using methods well known in the art.
  • Clone HBS6-1 contained an apparently full-length cDNA with a nested sequence corresponding to NAC sequence.
  • NACP protein was expressed in E. coli using pSENACP expression vector.
  • Plasmid pHBS6-1 was digested with Af ⁇ , treated with Klenow polymerase to generate a blunt end, and then digested with ⁇ /ocI to release the coding region.
  • This 1.2-kb Nco ⁇ -Afl ⁇ NACP cDNA fragment containing the entire coding sequence and 3' nontranslated region was ligated into a bacterial expression vector, pSE380 (Invitrogen), previously linearized by digestion with
  • Resultant pSENACP expresses NACP protein under the control of trp/lac fusion promoter which is inducible with IPTG.
  • pSENACP was amplified in E. coli HB101.
  • RNA preparation Procedures for RNA preparation, electrophoresis, and hybridization are those routinely used. Briefly, total RNA was isolated from different human tissues. RMA (10 ⁇ g) was electrophoresed on a 1% formaldehyde-agarose gel and blotted to a nitrocellulose membrane. Hybridization was carried out in 50% formamide, 5 x SSPE, 5 x Denhardt's, 0.5% SDS, 100 ⁇ g/ml denatured salmon sperm DNA, and 10% dextran sulfate at 42° C, and exposed for 3 days at -80°C. A higher stringency wash of 0.1 x SSC, 0.1% SDS at 65°C was also employed.
  • the deduced amino acid sequence shows that the X and Y peptides are located immediately next to each other in the middle of the precursor protein
  • NACP Neither an apparent signal peptide sequence nor canonical N-linked glycosylation sites were found.
  • Tissue homogenates were prepared from cytosolic fractions of frontal cortex from patients with typical and neuropathological features of AD obtained from the Alzheimer's Disease Research Center (San Diego, CA). Procedures for human brain preparation, electrophoresis, and immunoblotting detection have been reported by E. Masliah, ef al. (J. Neurosci, 10:2113-2124, 1990). Briefly, proteins were electrophoresed on a 16% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. Immunoblotting detection was performed using anti-X1 antibody (1 :1500 dilution) and 125 l-protein A. To absorb anti-X1 antibody, 200 ⁇ g/ml X1 fragment (SEQ. I.D. NO. 6) or the control peptide (EGYQDYEPEAC) (SEQ. I.D. NO. 8) were used.
  • the anti-Y antibody stained dozens of bands in addition to the M r 19K band (data not shown). Protein staining of the M r 19K band was abolished when either the anti-X1 or the anti-Y antibody was preabsorbed with its corresponding peptide fragment as shown in FIGURE 3, lane 3. However, the anti-X1 positive M r 40 band was not blocked by preabsorption and was not detected with anti-Y antibody, indicating that this band is not specific to NACP.
  • NACP protein derived from the cDNA isolated in .Example 3 above was produced in vitro. pHBS6-1 was digested with Aflll, treated with Klenow polymerase to generate a blunt end, and then digested with Ncol to release the coding region. This 1.2kb Ncol-Aflll NACP cDNA fragment of Sequence I. D. No. 1 containing the entire coding sequence and 3'-nontranslated region was ligated into a bacterial expression vector, pSE380 (Invitrogen, San Diego, CA), previously linearized by digestion with Ncol and Smal.
  • pSE380 Invitrogen, San Diego, CA
  • the resultant vector pSENACP expresses NACP protein under the control of trp/lac fusion promoter which is inducible with IPTG.
  • pSENACP was amplified in E. coli HB101 using techniques as described in Sambrook, supra and others.
  • a vector pSE380 without NACP cDNA was also transfected in E coli as a control.
  • Western Blot analysis as shown in FIGURE 3, lane 3, the bacterially expressed protein of M r 19K comigrated with the homogenate-derived protein, confirming the identity of the homogenate-derived protein.
  • NACP amino acid sequence of NACP was examined for distinctive structural features.
  • the NACP protein is characterized by repetitive motifs.
  • the KTKEGV motif is repeated seven times, but the amino acid positions 2 to 6 are sometimes substituted.
  • amino acids 48-56 and 70-78 of the NACP protein are homologous.
  • a computer homology search FASTA program, in the UCSD BAX/VMS DNA protein sequence analysis system
  • EMBL/GenBank Libraries DNA sequence data base
  • RNA preparation Procedures for RNA preparation, electrophoresis, and hybridization have been described previously (T. Saitoh, et al., Cell, 58:615-622, 1989). Briefly, total RNA was isolated from different human tissues as described in Chirgwin, J.M., et al. (Biochemistry, 18:5294-5299, 1979). RNA (10 ⁇ g) was electrophoresed on a 1 % formaldehyde-agarose gel and blotted to a nitrocellulose membrane.
  • Hybridization was carried out in 50% formamide, 5 x SSPE, 5 x Denhardt's, 0.5% SDS, 100 ⁇ g/ml denatured salmon sperm DNA, and 10% dextran sulfate at 42 °C for 15 hr with 32 P-labeled 1.1 -kb NACP cDNA which includes the X and Y sequence with a 3'-noncoding sequence.
  • the membrane was washed with 0.1 x SSPE, 0.1% SDS at 42°C, and exposed for 3 days at -80°C. A higher stringency wash of 0.1 x SSC, 0.1% SDS at 65° C was also employed.
  • a Northern blot was obtained from Clontech (Palo Alto, CA, #7760-1 , Lot 32409).
  • Panel A was probed with NACP cDNA and, as a control, panel B was probed with glyceraldehyde-3-phosphate dehydrogenase (GAPD) cDNA (ATCC, #57090). Briefly, the membrane was washed with 0.1 x SSPE, 0.1% SDS at 42°C, and exposed for 3 days at -80°C. The same pattern of signals was obtained after a higher stringency wash with 0.1 x SSC, 0.1% SDS at 65°C.
  • GPD glyceraldehyde-3-phosphate dehydrogenase
  • FIGURES 5A and 5B Comparable patterns of mRNA were observed in both normal and AD neocortex and cerebellum as shown in FIGURE 5D. Since
  • HBS6-1 is 1560 nucleotides long it probably corresponds to the shorter transcript.
  • a minor 1 kb band visible in FIGURE 5 D is believed to represent a transcript with a shorter 3' non-coding region resulting from the use of polyadenylation signals at 1023 bp or 1079 bp. It was discovered that the ratio of the different-sized transcripts varies depending on the age and origins of tissue employed as shown in FIGURE 5. The presence of the 3.6 kb transcript for NACP may be explained by an alternative splicing mechanism that is under developmental and/or tissue specific regulation.
  • EXAMPLE 8 NAC PEPTIDE AGGREGATION AND WESTERN BLOT ANALYSIS
  • a solution of synthetic NAC peptide (SEQ.ID.No.3) at a concentration of 600 ⁇ M was made in 50 mM boric buffer at pH 9.2. The solution was centrifuged at 100,000 x g for 1 hr and the supernatant was collected, neutralized by 1.5 N hydrochioride in 10 x PBS, and diluted in 1 x PBS (pH 7.4).
  • the aggregation of synthetic NAC peptide was followed by measurement of turbidity according to techniques known in the art (see, e.g., Jarrett, ef al., Biochemistry, 31 :12345-12352 (1992); and, Jarrett, et al., Cell, 73:1055-1058 (1993)).
  • Turbidity was measured at 400 nm daily for 7 days under the following two conditions: 1) various concentrations of NAC peptide: 10, 30, 100, 300 ⁇ M at 37°C, and 2) 300 ⁇ M of NAC peptide at various temperatures: 4°, 22°, and 37°C.
  • the peptide solutions/suspensions were mixed gently before each absorbance measurement.
  • the size of the aggregated NAC peptide was estimated by Western blot using anti-NAC-X1.
  • Six aliquots of peptide solution were prepared in boric buffer, lyophilized, and dissolved in water, neutralized, and diluted with PBS (phosphate buffered saline) to a final concentration of 300 ⁇ M. They were kept at 37°C for 0, 1 , 2, 3, 5, or 7 days, dissolved in Laemmli sample buffer (Laemmli, U. K., Nature, 227:680-685 (1970)), electrophoresed on 16% Tricine-SDS-polyacrylamide gel, and transferred to PVDF membrane for Western blot analysis.
  • PBS phosphate buffered saline
  • NAC peptide was solubilized in 50 mM boric buffer (pH 9.2) although it was also soluble in formic acid and 6 M guanidinium thiocyanate. NAC peptide aggregated in distilled water and PBS. Turbidity at 400 nm of NAC peptide solution in PBS increased with time. As shown in FIGURE 6 A, this increase was dependent on both the concentration of NAC peptide and the temperature (FIGURE 6 B). At Day 1 , 300 ⁇ M NAC peptide was required for the appreciable aggregation, whereas at Day 2 100 ⁇ M NAC peptide started to aggregate. The aggregation of NAC peptide at less than 30 ⁇ M was never remarkable. The aggregation of NAC peptide at 22 °C was comparable to that at 37 °C, although at 4 °C the aggregation was markedly delayed.
  • anti-NAC-X1 is not simply the conformational antibody, because it did not detect Ab blotted under the comparable conditions.
  • Anti-NAC-X1 stained amyloid cores in AD brain.
  • NAC peptide solution/suspension 300 ⁇ M at pH 7.4 was stored over 2 weeks at 37 ⁇ C to promote its aggregation.
  • the solution/suspension was centrifuged at 16,000 x g for 30 min.
  • the precipitate of peptide fibrils was collected, mixed in 1 ml of PBS solution containing 1 mM Congo red for 1 min, centrifuged at 16,000 x g for 5 min, and recollected. It was rinsed with 1 ml of distilled water for 1 min, and centrifuged at 16,000 x g for 5 minutes.
  • the peptide precipitate was placed on a glass microscope slide and allowed to dry. Birefringence was determined with an Olympus fluorescence microscope (model BHF) equipped with a polarizing filter apparatus (model BH-POL).
  • the NAC peptide aggregate was stained by Congo red. It exhibited green-gold birefringence when viewed with bright-field (FIGURE 8 A) and cross-polarization (FIGURE 8 B) microscopy. The stained peptides appear in the FIGURES as bright patches.
  • Electron microscopy of aggregated NAC peptide revealed clusters of fibrils deposited from the peptide suspension (FIGURE 9).
  • the diameter of fibrils was generally about an A.
  • the repeated structures were found in the fibrils.
  • the structure of NAC peptide fibrils was different from that of Ab in AD brain.
  • the NAC peptide has the following characteristics of amyloid: 1) green birefringence after Congo red staining when viewed with a polarizing microscope; 2) a typical structure under the electron microscope (fine, rigid, nonbranching fibrils); 3) insolubility in aqueous solution.
  • NAC was determined to be self-aggregating. However, it is important to note that the amyloid found in the brain tissue of patients with AD when viewed with electron microscopy is different from that formed by NAC aggregation. Thus, it is likely that NAC can not explain the global process of amyloid formation in AD. Rather, it is speculated that NAC is involved in only the initial process of amyloid formation and the major process of amyloidogenesis is due to the accumulation of Ab aggregation. Thus, NAC may serve as a seed to form amyloid as a minor component, on which Ab aggregate as a major component of amyloid. Further investigation will investigate the possibility that NAC may contribute to the process of Ab aggregation and amyloid forming and maturing.
  • rat brain sections were stained by anti-NACP(131 -140; SEQ.ID.No.6) and anti-NACP(1 -9; SEQ.ID.No.8) antisera.
  • SAB streptavidin-biotin-peroxidase staining method
  • Sprague-Dawley rats weighing 250 - 300 g were deeply anesthetized by sodium pentobarbital (Nembutal, Abbott Laboratories, North Chicago, IL ), perfused transcardially with 4% paraformaldehyde in PBS for 20 min, and the brain was removed and immediately placed in a postfixative, 4% paraformaldehyde solution, for 4 days at 4°C.
  • the brain was immersed in a 30% sucrose solution in PBS for 4 days at 4°C, frozen in -40°C hexane, and cut into 20- ⁇ m sections using a cryostat at -20°C.
  • Immunohistochemistry was performed according to the modified SAB method. Sections were rinsed for 3 x 5 min in PBS, incubated for 10 min in PBS including 0.1% Triton X-100, and incubated for 20 min with 3% H2O2 to inhibit endogenous peroxidase. They were then incubated for 10 min with 10% normal goat serum (NGS) (Nichirei, Tokyo, Japan) in PBS and incubated for 18 hr at 4 ⁇ C with anti-NACP(131 -140) or anti-NACP(1 -9) antiserum in PBS containing 1 % BSA.
  • NGS normal goat serum
  • Sections were rinsed for 3 x 5 min in PBS and incubated with biotinylated goat anti-rabbit-IgG solution (Nichirei, Tokyo, Japan) for 10 min. They were then rinsed for 3 x 5 min in PBS, incubated with streptavidin-peroxidase solution (Nichirei, Tokyo, Japan) for 5 min, and rinsed for 3 x 5 min in PBS. NACP-positive structures were visualized by incubating the tissue in 0.05% diaminobenzidine with 0.01 % H2O2 in 0.61 M Tris/HCI buffer (pH 7.4) for 5 - 15 min. Specificity of the immunohistochemical reaction was confirmed by the absence of staining in adjacent tissue sections incubated with preabsorbed antiserum.
  • Double-immunostaining was performed with antisera against NACP and synaptophysin as described previously (Masliah, ef al., Exp.Neurol., 113:131-142, 1991). After treatment with 0.1 % Triton X-100 and 3% H2O2, sections were incubated for 1 hr with 5% normal horse serum (NHS) (Vector Labs, Inc., Burlingame, CA ), 10% NGS (Vector Labs, Inc.), and 2% BSA in PBS.
  • NHS normal horse serum
  • the intensity of staining with anti-NACP(131-140) was relatively strong in the gray matter of the cerebral cortex (layers II, III, and V), anterior olfactory nucleus, caudate putamen, nucleus accumbens, hippocampus, ventral tegmental area, substantia nigra, pontine nuclei, and cerebellar cortex as shown macroscopically in FIGURE 10 A.
  • the staining pattern of sections using anti-NACP(1 -9) antisera was identical to that of anti-NACP(131-140). This staining was abolished by preincubation of the antisera with the corresponding peptide.
  • FIGURES 10 B-D The results of microscopic observation of the sections stained using the SAB method are shown in FIGURES 10 B-D.
  • cerebellum FIG. 10 B
  • the molecular layer and granule cell layer were stained, but the medullary layer and the Purkinje cell perikarya were not stained.
  • the perikarya of cells including stellate, basket, Golgi, granule, and glial cells were not stained.
  • An intermediate region where neurites were extended was stained with a "punctate" pattern.
  • Brains of young adult Sprague-Dawley rats weighing 250 - 300 g were separated into 10 portions as follows: olfactory bulb, frontal cortex, striatum, hippocampus, hypothalamus, thalamus, midbrain, cerebellum, pons & medulla oblongata, and pituitary gland.
  • APP and synaptophysin quantification 40 ⁇ g protein of either cytosolic or particulate fraction was loaded on a 10% SDS-polyacrylamide gel and blotted to nitrocellulose membrane.
  • the mouse monoclonal antibody against the N-terminal of APP 22C11
  • Boehringer Mannheim Weidemann, et al., Cell, 57:115-
  • Immunoreactive NACP protein bands were detected as a molecular mass of 19,000 Da in the cytosolic fraction of brain homogenate. Since APP protein bands were observed at molecular masses of 75,000 - 105,000 Da in the cytosolic fraction and at molecular masses of 100,000 - 115,000 Da in the particulate fraction by 22C11 , a monoclonal antibody against APP (Weidemann, et al., 1989, supra), the sum of signal intensity in both fractions was used as the amount of APP. Synaptophysin protein bands were observed with a molecular mass of 38,000 Da in the particulate fraction of brain sample by a mouse monoclonal antibody, SY38.
  • the concentration of NACP was high in the telencephalon (end-brain areas), including the olfactory bulb, frontal cortex, striatum, and hippocampus, intermediate in the hypothalamus and thalamus, and low in the midbrain, cerebellum, pons & medulla oblongata, and pituitary gland.
  • APP and synaptophysin were more evenly distributed in most portions of brain. However, the amount in the pituitary gland was small.
  • AD brain tissue was obtained from the frontal cortex of patients with typical clinical and neuropathological features of AD (supplied by the Alzheimer's Disease Research Center, San Diego, CA). Using the double immunolabeling and laser confocal microscopy techniques described in the preceding E ⁇ xamples, the quantity of NACP in presynaptic terminals, as well as diffuse and mature amyloid plaques, was compared in tissue from AD brain and "normal" brain tissue.
  • FIGURES 15 through 16 the number of NACP containing presynptic terminals is significantly decreased in AD brain tissue as compared to normal brain tissue-by 30-40%. Further, although the overall synaptic populations are decreased in AD brain tissue, there is a significant increase in the quantity of NACP present in each presynaptic bouton of AD brain tissue, indicating a compensatory mechanism for the loss of synapses (FIGURES 15 through 16). ln addition, anti-NAC antibodies (as described elsewhere above) bound about 35% of the diffuse plaques and about 55% of the mature plaques present in the AD brain tissue tested (FIGURE 17).
  • Double immunolabeling of tissue with anti- ⁇ -amyloid antibodies and anti-NAC antibodies showed that NAC is also more abundant than ⁇ - amyloid in AD brain tissue (FIGURE 18). Further, control tissue samples obtained from elderly persons without AD but whose brain tissue contained relatively small groups of diffuse plaques did not react with anti-NAC antibodies, while tissue samples obtained from persons suffering from either early or advanced cases of AD that contained a relatively large number of diffuse plaques as well as mature plaques reacted strongly with anti-NAC antibodies in about 30-50% of the plaques (FIGURES
  • NACP amino acid sequence showed 95% identity with that of rat synuclein 1 , a synaptic/nuclear protein previously identified in rat brain, indicating that NACP is the human homologue of rat synuclein 1.
  • Rat SYN2 also showed high homology to NACP, howevere, approximate 50 amino acid sequence of C-terminal was different.
  • Rat SYN3 and human EST01420 identified by random sequencing of human brain cDNAs (Adams, et al., Nature, 355: 632-634, 1992), had homologous sequence to N-terminal portion of NACP, but neither of them included NAC portion. Torpede synuclein also showed homologous sequence with 16 amino acids insertion between the residue 28 and 29 of NACP.
  • HSPTPS Homo sapiens putatively transcribed partial sequence
  • Control data was generated from cryostat sections taken from the cortex of normal and AD cases which were incubated with radiolabelled and unlabelled ⁇ -amyloid and substance P.
  • Use of intracerebral injections of amyloid into the rat brain as an animal model mimics the deposits of amyloid in the plaques of the patients with AD.
  • this animal model is not a model of AD per se, it is a model of amyloid deposits in the brain, which is one of the most important diagnostic hallmarks of AD.
  • This animal model will, therefore, be useful in testing whether NAC/NACP peptides administered as described with respect to ⁇ -amyloid peptides will cross the blood/brain barrier.
  • Control experiments where 125 l /3-amyioid (1- 28) was substituted by vehicle alone showed only background CPM's, thus indicating that 12 l /3-amyloid (1-28) injected into the circulation crossed the blood/brain barrier and bound the unlabelled amyloid injected in the brain.
  • NAC/NACP peptides of 28 amino acids in length or shorter will also cross the blood/brain barrier.
  • the CPM measurements reported were obtained by spectrophotometric analysis of fresh samples of brain tissue (taken from living, anaesthetized rats). For comparison, cryostat sections were also taken from rats in each model group for in vitro analysis using the AMBIS 4000 radioimaging acquisition and analysis system (i.e., computed tomography system) (Ambis, San Diego, CA).
  • AMBIS 4000 radioimaging acquisition and analysis system i.e., computed tomography system
  • ADDRESSEE Spensley Horn Jubas & Lubitz
  • B STREET: 1880 Century Park East - Suite 500
  • ATTORNEY/AGENT INFORMATION (A) NAME: Ho ells, Stacy L.
  • TELECOMMUNICATION INFORMATION (A) TELEPHONE: (619) 455-5100 (B) TELEFAX: (619) 455-5110 (2) INFORMATION FOR SEQ ID NO:l:
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • Sequence I.D. No. 1 oligonucleotide is a sequence for cDNA encoding NACP polynucleotide.
  • Sequence I.D. No. 2 is an amino acid sequence for NACP polypeptide.
  • Sequence I.D. No. 3 is an amino acid sequence for NAC polypeptide.
  • Sequence I.D. No. 4 is an amino acid sequence for X peptide.
  • Sequence I.D. No. 5 is an amino acid sequence for Y peptide
  • Sequence I.D. No. 6 is an amino acid sequence for fragment X1
  • Sequence I.D. No. 7 is an amino acid sequence for fragment Y
  • Sequence I.D. No. 8 is an amino acid sequence for a control peptide.
  • oligonucleotide is a sense primer (X1) for the N-terminal half of X peptide.
  • oligonucleotide is an antisense primer (X2) for the C- terminal half of X peptide.
  • oligonucleotide is a sense primer (Z) for a region flanking the EcoRI cloning site of lambda gt11.
  • Sequence I.D. No. 12 oligonucleotide is an antisense primer ( ⁇ Z) for a region flanking the EcoRI cloning site of lambda gt11.

Abstract

On décrit un gène, le NACP, (précurseur d'un nouveau composant amyloïde) nucléotide et sa séquence d'acides aminés. On décrit aussi des procédés diagnostiques et thérapeutiques d'utilisation du nucléotide et des séquences polypeptidiques de ce NACP. Le polypeptide du NACP est un précurseur du NAC (nouveau composant amyloïde), peptide qui est associé aux dépôts amyloïdes présents dans le cerveau des patients qui présentent des caractéristiques neuropathologiques typiques de la maladie d'Alzheimer. On décrit aussi la séquence d'acides aminés du NAC et de deux de ses fragments contigus, les peptides X et Y. On décrit enfin des procédés diagnostiques et thérapeutiques concernant des troubles amyloïdes associés au NAC.
PCT/US1994/009789 1993-08-30 1994-08-29 Nouveau composant amyloide lie a la maladie d'alzheimer et procedes d'utilisation WO1995006407A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11439393A 1993-08-30 1993-08-30
US08/114,393 1993-08-30

Publications (1)

Publication Number Publication Date
WO1995006407A1 true WO1995006407A1 (fr) 1995-03-09

Family

ID=22354920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009789 WO1995006407A1 (fr) 1993-08-30 1994-08-29 Nouveau composant amyloide lie a la maladie d'alzheimer et procedes d'utilisation

Country Status (1)

Country Link
WO (1) WO1995006407A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018917A2 (fr) * 1998-09-25 2000-04-06 Amgen Inc. Super mutants d'alpha-synucleine pouvant accelerer l'agregation d'alpha-synucleine
US6504080B1 (en) 1999-10-15 2003-01-07 Novartis Ag Transgenic animal model for neurodegenerative disorders
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7727957B2 (en) 2002-11-01 2010-06-01 Janssen Alzheimer Immunotherapy Treatment and delay of outset of Parkinson's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7919088B2 (en) 2003-10-31 2011-04-05 Elan Pharmaceuticals, Inc. Treatment and delay of onset of synucleinopathic and amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8092801B2 (en) 2007-02-23 2012-01-10 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
AU2005295248B2 (en) * 2004-10-19 2012-05-17 Prothena Biosciences Limited Truncated fragments of alpha-synuclein in Lewy Body Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2016061389A2 (fr) 2014-10-16 2016-04-21 Genentech, Inc. Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
EP3026057A2 (fr) 2009-03-09 2016-06-01 Ramot at Tel Aviv University Ltd. Compositions pour la prévention et le traitement de maladies neurodégénératives
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
EP2576609B1 (fr) * 2010-05-25 2018-11-14 Vib Vzw Marqueur épitopique pour des applications fondées sur l'affinité
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PATHOLOGY, Vol. 141, No. 4, issued October 1992, PRICE et al., "Amyloidosis in Aging and Alzheimer's Disease", pages 767-772. *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 120, No. 3, issued 16 May 1984, GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", pages 885-890. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 82, issued June 1985, MASTERS et al., "Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome", pages 4245-4249. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 90, issued December 1993, UEDA et al., "Molecular Cloning of cDNA Encoding an Unrecognized Component of Amyloid in Alzheimer Disease", pages 11282-11286. *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051363B2 (en) 1997-12-02 2015-06-09 Janssen Sciences Ireland Uc Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US8535673B2 (en) 1997-12-02 2013-09-17 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7893214B2 (en) 1997-12-02 2011-02-22 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US8034339B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8034348B2 (en) 1997-12-02 2011-10-11 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US8642044B2 (en) 1997-12-02 2014-02-04 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2000018917A2 (fr) * 1998-09-25 2000-04-06 Amgen Inc. Super mutants d'alpha-synucleine pouvant accelerer l'agregation d'alpha-synucleine
WO2000018917A3 (fr) * 1998-09-25 2000-11-02 Amgen Inc Super mutants d'alpha-synucleine pouvant accelerer l'agregation d'alpha-synucleine
US6504080B1 (en) 1999-10-15 2003-01-07 Novartis Ag Transgenic animal model for neurodegenerative disorders
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US8128928B2 (en) 2002-03-12 2012-03-06 Wyeth Llc Humanized antibodies that recognize beta amyloid peptide
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7727957B2 (en) 2002-11-01 2010-06-01 Janssen Alzheimer Immunotherapy Treatment and delay of outset of Parkinson's disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9879071B2 (en) 2003-05-19 2018-01-30 Prothena Biosciences Limited Antibodies to alpha synuclein
US7871615B2 (en) 2003-05-30 2011-01-18 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7919088B2 (en) 2003-10-31 2011-04-05 Elan Pharmaceuticals, Inc. Treatment and delay of onset of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7910333B2 (en) 2003-11-08 2011-03-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US8673593B2 (en) 2003-11-08 2014-03-18 Elan Pharmaceuticals, Llc Antibodies to alpha-synuclein
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
AU2005295248B2 (en) * 2004-10-19 2012-05-17 Prothena Biosciences Limited Truncated fragments of alpha-synuclein in Lewy Body Disease
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8092801B2 (en) 2007-02-23 2012-01-10 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9644025B2 (en) 2007-10-17 2017-05-09 Wyeth Llc Immunotherapy regimes dependent on ApoE status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP3026057A2 (fr) 2009-03-09 2016-06-01 Ramot at Tel Aviv University Ltd. Compositions pour la prévention et le traitement de maladies neurodégénératives
EP2576609B1 (fr) * 2010-05-25 2018-11-14 Vib Vzw Marqueur épitopique pour des applications fondées sur l'affinité
WO2016061389A2 (fr) 2014-10-16 2016-04-21 Genentech, Inc. Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11827695B2 (en) 2017-02-17 2023-11-28 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof

Similar Documents

Publication Publication Date Title
WO1995006407A1 (fr) Nouveau composant amyloide lie a la maladie d'alzheimer et procedes d'utilisation
Barelli et al. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides: Their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer’s disease and cerebral amyloid angiopathy cases
EP0826042B1 (fr) Sequences genetiques et proteines associees a la maladie d'alzheimer et leur utilisation
CA2174632C (fr) Procede de detection d'inhibiteurs de la production de peptides beta-amyloides
US5441870A (en) Methods for monitoring cellular processing of β-amyloid precursor protein
DE69333144T2 (de) Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
US6242416B1 (en) Inhibition of β-amyloid binding to the p75 nerve growth factor receptor
US11932908B2 (en) Compositions and methods for diagnosis and treatment of epilepsy
CA2268029C (fr) Applications therapeutiques et de diagnostic de la laminine et de fragments de proteine derivee de la laminine
US5470955A (en) Antibodies which specifically bind mcl-1 polypeptide
WO1998022499A9 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
WO1998022499A2 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
JP4649602B2 (ja) 活性依存性向神経第▲ｉｉｉ▼因子（ａｄｎｆ▲ｉｉｉ▼）
JP2000516087A (ja) アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
CA2348430A1 (fr) Genes et proteines specifiques aux ovaires
JP5379119B2 (ja) アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
AU2004203875A1 (en) Methods and compositions for the detection of soluble beta-amyloid peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA